Genitourinary Cancers

Despite evidence supporting its efficacy, chemotherapy is not routinely administered to patients with muscle-invasive bladder cancer.

A cell-cycle gene array test demonstrated independent value for predicting metastatic progression after surgery for organ-confined renal cell carcinoma (RCC) of clear cell histology, a retrospective study of patient data showed.

In the age of social media, simply having a website isn't enough. To keep existing patients and attract new ones, large urology group practices need to build websites that are connected to social media outlets at every turn, said Peter M. Knapp, Jr, MD.

Self-reported physical activity significantly improved the odds that a person would not die of bladder cancer, a review of a national health information database showed.

Moben Mirza, MD, assistant professor of urology at the University of Kansas Medical Center, discusses a study presented at the 2014 AUA Annual Meeting that evaluated gender and race variation in the workup of hematuria.

Eugene Y. Rhee, MD, chief of urology, Kaiser Permanente, discusses workplace violence in urology practices.

In urology, we are faced with very difficult and challenging times.

A trial (NCT01582672) that will pair a targeted treatment with a vaccine therapy for firstline treatment of renal cell carcinoma (RCC) is recruiting at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute.

Brian Rini, MD, associate professor, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, discusses the role of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma (RCC).

Richard S. Pelman, MD, Juan A. Reyna, MD, and David F. Penson, MD, all large urology organization leaders, cited managing bureaucracy, PSA screening, and in-office ancillaries as top priorities.

Obesity increases the chance that someone will get the clear-cell form of renal cell carcinoma (ccRCC). But once an obese patient has the disease, he's likely to survive longer than a non-obese patient.

James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, gives an overview of emerging treatments for patients with kidney cancer.

David F. Penson, MD, MPH, director, Center for Surgical Quality and Outcomes Research Professor of Urologic Surgery, Paul V. Hamilton, M.D. and Virginia E. Howd Chair in Urologic Oncology, professor of medicine, Vanderbilt University Medical Center, discusses some of the advantages and disadvantages of a large urologic practice.

During the annual meeting of the Large Urology Group Practice Association (LUGPA) in Chicago in November 2013, the organization's president, Deepak A. Kapoor, MD, completed his 2-year term and handed the gavel to incoming president Juan A. Reyna, MD.

When I first entered practice in 1990, I was fortunate to have senior partners and colleagues who offered sage advice, much of it based on retrospective analysis of their own successes and failures over time.